The Westin Grande Sukhumvit Bangkok
Heliae, a leader in development of advanced algae production technologies, recently announced the launch of operations at its first commercial facility in Gilbert, Arizona.
It’s a very crucial milestone as Heliae already has a well-established algae platform VolarisTM that combines the best of existing algae production models, utilising both sunlight and low-cost carbon feedstocks for optimised output. The Volaris platform promises to reduce capital costs, improve contamination control and increase productivity and product optionality as it is a hybrid of known phototrophic and heterotrophic models and is called mixotrophic algae production platform.
As this algae production platform can be customised, Heliae will be able to produce a variety of products and ingredients for multiple markets. To begin with, the commercial facility aims at producing high-value algae products for nutraceutical and personal care markets.
Listen to Mr. Mike Rohlfsen, Director of Business Development, Heliae Development, LLC at CMT’s 6th Algae World Asia opening in Bangkok, Thailand on 28-29 October 2013. He will enlighten the audience on ‘Bringing novel algae based products to the health and beauty industry’.
Thailand based Loxley Public Company has recently announced that it will invest about Bt 1 billion in the production of algae-based biodiesel. The project will begin with a demonstration plant, and once that becomes successful, Loxley plans to commence construction of a pilot plant on 400 rai of land. The pilot plant is likely to begin operations within the next year.
Once fully operational, the company aims to produce approximately 90,000 kilograms of algae per day which will help in the production of about 30,000 litres of biofuel on a daily basis.
Biofuel is environment friendly. Therefore, the production of biofuel using algae is expected to consume about 180 tons of carbon dioxide per day, or about 10% of the total CO2 produced by the power plant. This implies the project is in the right path of reducing CO2 emission in the near future.
Loxely has already shown its commitment towards alternative energy development, particularly algae oil innovation, when the firm along with the Ratchaburi Electricity Generating Holding and Bangchak Petroleum signed a memorandum of understanding with the Alternative Energy Development and Efficiency Department to conduct R&D in this area last year.
Mr. Nattapon Dejvitak, VP, Business Development, LoxelyPublic Company is co-presenting a paper on ‘Loxley Algae Bio-fuel Demonstration Plant’ along with Mr. Anthony Bates, General Counsel & Director of Asia Operations, MBD Energyat the 6th Algae World Asia to be held from 28-29 October 2013.
For information about the event, please visit the event page.
Contact Ms. Huiyan at email@example.com or Tel: (65) 63469113.
Triton Algae Innovations completed its Series-A equity financing worth $5 million recently with investment from Heliae Technology Holdings, Inc., a leader in the production of algae to create high-value products.
Triton, a path breaking startup in the field of synthetic biology, is expected to use these funds to enhance its ongoing research and development programs, including expansion of its product – PhycoLogix™ platform, that uses algae to produce novel products with advantages over traditional protein expression systems. The funding will also be used for commercialising Triton’s very first product line PhycoShield™.
Former Sapphire Energy founders Dr. Jason Pyle and Dr. Stephen Mayfield founded Triton. Dr. Mayfield is a much respected algal scientist across the world. Under his stewardship, Triton has produced PhyscoShield™ product line, more specifically Mammary Associated Amyloid (MAA) that can save millions of humans and livestock from diarrheal deaths. It’s reported that diarrhea is the prime cause for the death of nearly 2 million plus human beings and 20% of the world’s livestock. Triton plans to make MAA commercially available in 2014.
Apart from this, Triton is also doing high level research in the field of oncology to bring some solutions in the battle against cancer. Dr. Mayfield is the main scientist behind Triton’s oncology products. The therapies developed by Triton have already proven to be highly efficient in combatting cancers.
Triton is innovative in developing proteins. It produces complex proteins, enzymes, and other biologics for sectors such as agriculture, pharmaceutical, and retail markets, which marks a complete shift from the traditional platforms developed with algae.
To know more about the latest trends in the algae industry, CMT’s 6th Algae World Asia is the place to be on 28-29 October, 2013 in Bangkok, Thailand as Dr. Jason Pyle, founder and CEO of Triton is contributing a paper on ‘Commercializing Advanced Biologics in Algae’ at the conference.
Visit the event page for more details.
For more information about the event, contact Ms Huiyan at firstname.lastname@example.org or Tel: (65) 63469113